Is Zepbound the Same as Tirzepatide? Brand, Generic and Compounded

The labeled uses above come from the current Zepbound and Mounjaro prescribing information on DailyMed, the National Library of Medicine's label database, read on October 7, 2026 (Zepbound label; Mounjaro label). Labels change, so check the current version before relying on any row.

Tirzepatide and Zepbound are two names at two levels. Tirzepatide is the nonproprietary name of the molecule. Zepbound is a trademark Eli Lilly puts on a finished, FDA-approved tirzepatide injection. The Zepbound label states it directly: Zepbound contains tirzepatide.

So the difference between Zepbound and tirzepatide is the difference between a product and its active ingredient. Every Zepbound pen contains tirzepatide. Not every product that contains tirzepatide is Zepbound.

Tirzepatide activates two hormone receptors, GIP and GLP-1. Our comparison of semaglutide vs tirzepatide explains what that dual action means, and Zepbound vs Wegovy compares the two brand-name weight-management products.

Mounjaro is tirzepatide as well. Zepbound and Mounjaro share one molecule, one manufacturer and the same six strengths. What separates them is the FDA-approved labeling.

• Zepbound is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight and at least one weight-related condition. It is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Mounjaro is indicated to improve glycemic control in adults and children 10 years and older with type 2 diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them.

The label is what an insurer reads. A plan may cover Mounjaro for diabetes and exclude Zepbound for weight management, even though the molecule is identical.

The Zepbound label adds a limitation that follows from this: because Zepbound contains tirzepatide, using it with another tirzepatide product or with any GLP-1 receptor agonist is not recommended.

Compounded tirzepatide is a preparation that a state-licensed compounding pharmacy makes for an individual patient, against a prescription, using tirzepatide as the active ingredient. It is usually dispensed in a vial rather than in Lilly's pen.

Compounded tirzepatide is not FDA-approved. The FDA's own wording is that compounded drugs do not go through the agency's review for safety, effectiveness or quality before they are marketed (FDA, content current as of October 1, 2026).

The same FDA page says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. It also lists, as a warning sign, any company claiming a compounded drug is the same as an FDA-approved one. It reports more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026, and it cautions that such events are likely underreported and that it is not always possible to tell whether the drug caused a reported event.

Zepbound and compounded tirzepatide both name tirzepatide as the active ingredient. They differ in five ways that matter to a patient.

• Approval. Zepbound is FDA-approved. Compounded tirzepatide is not approved for any use.
• Evidence. The clinical trials tested Lilly's product. No compounded tirzepatide preparation was studied in them.
• Ingredients. Zepbound's single-dose pens and vials list sodium chloride, a sodium phosphate buffer and water as inactive ingredients; its multi-dose vial and KwikPen also contain benzyl alcohol, glycerin and phenol. A compounded formula is whatever the pharmacy prepares, and some add other ingredients such as vitamin B12.
• Form and dosing. Zepbound comes in fixed strengths. Compounded tirzepatide usually means measuring each dose from a vial with a syringe. The FDA has received adverse-event reports that may be related to dosing errors with compounded semaglutide, and to compounded semaglutide or tirzepatide prescribed at doses beyond the approved labeling.
• Oversight. Zepbound's manufacturing quality is part of what the FDA reviews for approval. State-licensed compounding pharmacies are regulated mainly by state boards, and federal law does not require them to report adverse events to the FDA.

Zepbound's approvals do not transfer to a compounded version. Compounded tirzepatide is not approved for weight management and is not approved for sleep apnea. Those indications belong to the product that earned them.

Zepbound's approvals rest on Eli Lilly's SURMOUNT program. Three results explain most of the interest in the drug.

• SURMOUNT-1 assigned 2,539 adults with obesity or overweight, without diabetes, to tirzepatide or placebo for 72 weeks. Average weight change was −15.0% at the 5 mg dose the trial used, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% with placebo (Jastreboff et al., 2022).
• SURMOUNT-5, an open-label trial funded by Eli Lilly, compared tirzepatide with semaglutide in 751 adults with obesity. Average weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide (Aronne et al., 2025).
• SURMOUNT-OSA studied adults with moderate to severe obstructive sleep apnea and obesity. In the trial of participants not using PAP therapy, breathing interruptions fell by 25.3 events per hour with tirzepatide and 5.3 with placebo at 52 weeks (Malhotra et al., 2024).

These are averages from controlled trials of the brand-name product. Individual results vary widely, and no figure here predicts what one person will lose.

Compounded semaglutide and tirzepatide are not FDA-approved, are not the same as the brand-name products, and were not studied in these trials.

No. There is no FDA-approved generic Zepbound. The FDA's approved-drug database lists two tirzepatide applications, Zepbound and Mounjaro, and Eli Lilly holds both (Drugs@FDA, checked October 7, 2026).

A generic is a specific legal category. The manufacturer must show the FDA that its copy matches the brand-name drug before it can be sold. Compounded tirzepatide has not been through that process, so it is not a generic for Zepbound, whatever an advertisement calls it.

Compounded tirzepatide became common while brand-name tirzepatide was on the FDA's drug shortage list. That period is over, and the rules are narrower now. The dates below come from the FDA's running statement for compounders (FDA, last updated April 1, 2026).

• December 19, 2024. After re-evaluating an earlier decision, the FDA determined that the tirzepatide injection shortage was resolved.
• February and March 2025. The FDA set its enforcement-discretion period for state-licensed (503A) pharmacies to run until February 18, 2025 or a pending court ruling, whichever was later. The court ruled on March 5, 2025, and the FDA then confirmed that the period had ended. For outsourcing facilities (503B) it ran to March 19, 2025.
• April 1, 2026. The FDA's most recent update states that tirzepatide and semaglutide do not appear on its drug shortage list or on the 503B bulks list.

What remains is the standing rule for 503A pharmacies. A pharmacy may not regularly compound a drug that is essentially a copy of a commercially available product. The exception is a prescriber who determines and documents that a compounded change produces a significant difference for an identified patient. That is a judgment about one patient, not a general permission.

Switching from compounded tirzepatide to Zepbound, or the other way, is a prescriber's decision. Three points usually come up.

• Do not assume the doses match. A compounded vial's concentration is set by the pharmacy, so the amount drawn into a syringe has to be converted by the prescriber, not estimated.
• Do not overlap them. The Zepbound label advises against using it with other tirzepatide-containing products.
• Tell the new prescriber exactly what you were taking, including the pharmacy, the concentration on the vial and any added ingredients.

The order of the questions matters more than the answer to any one of them.

• Does a labeled use fit you? If you have obstructive sleep apnea with obesity, only Zepbound is approved for it.
• Will your plan cover Zepbound? Ask about prior authorization and appeals before assuming a denial is final.
• Can you afford the brand without coverage? Eli Lilly sells Zepbound directly to self-pay patients through LillyDirect. Its prices and terms change, so check them at the source.
• Is there a medical reason for a compounded preparation? That is the prescriber's determination to make and document.
• Who is the pharmacy? For a compounded prescription, the pharmacy's state license and sterile-compounding standards are the quality controls you have.

Protocol MD sells compounded tirzepatide, so we have a commercial interest in this question. Read this article with that in mind. We do not sell Zepbound or Mounjaro.

The Protocol MD tirzepatide protocol has three steps: an online intake that screens for the contraindications above, a review by a US-licensed physician who decides whether a prescription is appropriate, and dispensing by a licensed 503A compounding pharmacy only if the physician approves. Protocol MD serves all 50 states. Your card is authorized at checkout and charged only if a physician approves your prescription.

If you can get Zepbound through insurance or can afford it directly, it carries FDA approval and a trial record that a compounded preparation does not. If you want a physician to review your situation, start with the assessment.

Zepbound is tirzepatide: a brand name for an FDA-approved tirzepatide injection, labeled for chronic weight management and for obstructive sleep apnea in adults with obesity. Mounjaro is the same molecule with a diabetes label. Compounded tirzepatide uses the same drug name but is a separate, pharmacy-prepared product that is not FDA-approved, was not studied in the SURMOUNT trials and is not a generic. Decide with a prescriber, starting from the approved product and the coverage you can actually get.